This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Colorectal Cancer
and you are
over 20
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

The purposes of this study were to assess the safety, tolerability, pharmacokinetic interactions, and the Human Anti-Human Antibody of dalotuzumab in combination with cetuximab and irinotecan in participants with advanced or metastatic colorectal cancer in Japan.

Provided treatments

  • Biological: Dalotuzumab 10 mg/kg
  • Biological: Cetuximab
  • Drug: Irinotecan
  • Biological: Dalotuzumab 15/7.5 mg/kg
Tris trial is registered with FDA with number: NCT00925015. The sponsor of the trial is Merck Sharp & Dohme Corp. and it is looking for 20 volunteers for the current phase.
Official trial title:
A Phase I Study of MK-0646 in Combination With Cetuximab and Irinotecan in Patients With Advanced or Metastatic Colorectal Cancer